Keywords: la, jolla, pharma, jeopardy, after, pivotal, riquent
La Jolla Pharma in jeopardy after pivotal Riquent trial is abandoned as futile
Article | 23 February 2009
The USA's La Jolla Pharmaceutical's Phase III ASPEN trial of its Riquent (abetimus sodium; Marketletters passim), an investigational drug for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
